{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004129","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.790515+00:00","generated_at":"2026-05-28T05:23:33.700281+00:00","sec_items":["1.01","2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Climb Bio licenses MIL116 antibodies from Mabworks; reports $212.9M cash, runway through 2027","bullets":["Upfront $9M to Mabworks; up to $30M development/regulatory milestones for first indication.","Up to $832M commercial milestones across all products; tiered low-to mid-single-digit royalties.","Preliminary cash $212.9M and ~67.3M shares outstanding as of Dec 31, 2024.","Existing cash expected to fund operations, including budoprutug and CLYM116, through 2027.","Exclusive rights to MIL116 (CLYM116) outside China; non-exclusive rights for global trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004129","json":"https://secwatch.observer/filing/0001193125-25-004129.json","markdown":"https://secwatch.observer/filing/0001193125-25-004129.md","text":"https://secwatch.observer/filing/0001193125-25-004129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525004129/0001193125-25-004129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525004129/d851032d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:23:33.700281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}